Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Matt Dellatorre
Period: Reporting periods mapped to calendar 2025 Q2 – 2026 Q2 (5 quarters).
- Questions
- 6on tracked calls
- Challenge rate
- 0%none of 6 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 5with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 6 of 6 questions from 1 company
VTRSViatris6 questions · 5 reporting periods · 0 of 6 challenging
Calendar 2026 Q2
Could you comment on any recent interactions with the FDA regarding the label being opioid sparing?
Show response
Philippe deferred exact label language to the Oct/Nov negotiation window; Corinne cited up to $500 million peak sales; partial pending label.
Calendar 2026 Q1
could you comment on whether priority review is still a possibility there
Show response
Philippe said PDUFA date expected within weeks. Opioid-sparing language expected on label. Scott confirmed on track for $120M savings in 2026. Operating leverage visible with 3% revenue growth and 10% EBITDA growth. Corinne noted opioid-sparing in indication is helpful but not essential.
Calendar 2025 Q4
could you share your latest expectations in terms of the label, in particular, how you expect opioid sparing to be reflected there
Show response
Philippe confirmed extremely positive pre-NDA meeting with full alignment. Filing the next day. Anticipates opioid-sparing language in label but exact placement (indication vs clinical section) TBD. Scott said BD focused on in-market accretive growth assets, not early pipeline.
Calendar 2025 Q3
could you comment on any feedback thus far from the FDA regarding the potential for an opioid-sparing label
Show response
Philippe confirmed Phase 3 designed with FDA to support opioid-sparing label. Pre-NDA meeting scheduled within weeks to discuss. Scott said partnership discussions active but company can commercialize alone; would only partner if significantly additive.
should we think about '26 looking more like '25, where it is more kind of capital return? Or directionally, does '26 look more like that 50-50 balance
Show response
Scott reiterated balanced 3-5 year approach. 2025 leaned into buybacks given uncertainty. Cited Aculys Japan deal as example of desired BD profile. Would love to find in-market accretive US innovative products.
Calendar 2025 Q2
how much of a priority is growth at this point? And what level of growth are you now aiming for as we think about full year '26 and beyond
Show response
Scott declined to give a specific 2026 growth number but reaffirmed 50/50 capital allocation split between shareholder returns and business development. Focus on strategic accretive in-market assets. Doretta added visibility to low single-digit base business revenue growth.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| VTRS Viatris | 6 | 0%none of 6 questions |
- VTRSViatris · 6 questions0%none of 6 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | 2 | 0%none of 2 questions | 1 |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
| 2026 Q2 | 1 | 0%none of 1 question | 1 |
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q32 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q21 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Innovation & R&D4
- M&A3
- Product Launch2
- Capital Allocation2
- Regulation Policy1
- Cost Pressure1